Landscape Capital Management L.L.C. Acquires New Shares in BridgeBio Pharma, Inc. $BBIO

Landscape Capital Management L.L.C. bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,197 shares of the company’s stock, valued at approximately $605,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Jupiter Topco LLC purchased a new stake in BridgeBio Pharma in the 2nd quarter worth approximately $1,050,762,000. Janus Henderson Group PLC lifted its holdings in BridgeBio Pharma by 19.8% during the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock valued at $978,608,000 after purchasing an additional 2,178,556 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in BridgeBio Pharma during the second quarter valued at approximately $145,663,000. Pictet Asset Management Holding SA lifted its holdings in BridgeBio Pharma by 16.8% during the third quarter. Pictet Asset Management Holding SA now owns 1,690,829 shares of the company’s stock valued at $111,290,000 after purchasing an additional 242,703 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its position in shares of BridgeBio Pharma by 114.2% in the second quarter. Squarepoint Ops LLC now owns 1,191,732 shares of the company’s stock worth $88,760,000 after purchasing an additional 635,408 shares during the period. 99.85% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Neil Kumar sold 10,000 shares of BridgeBio Pharma stock in a transaction that occurred on Wednesday, November 18th. The stock was sold at an average price of $77.72, for a total transaction of $777,200.00. Following the completion of the transaction, the chief executive officer directly owned 485,686 shares in the company, valued at approximately $37,747,515.92. This trade represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the company’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $72.85, for a total transaction of $145,700.00. Following the completion of the transaction, the chief accounting officer owned 120,687 shares of the company’s stock, valued at approximately $8,792,047.95. This trade represents a 1.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 56,980 shares of company stock worth $4,332,346 in the last quarter. Company insiders own 14.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Jefferies Financial Group reissued a “buy” rating on shares of BridgeBio Pharma in a report on Monday, October 5th. Mizuho upped their price objective on BridgeBio Pharma from $96.00 to $110.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 1st. Bank of America increased their target price on BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Piper Sandler increased their target price on BridgeBio Pharma from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, October 19th. Finally, Wells Fargo & Company lifted their target price on BridgeBio Pharma from $98.00 to $102.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Nineteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $104.42.

Check Out Our Latest Research Report on BBIO

BridgeBio Pharma Price Performance

BBIO opened at $76.03 on Friday. BridgeBio Pharma, Inc. has a 12-month low of $62.50 and a 12-month high of $93.42. The business’s fifty day simple moving average is $70.30 and its 200-day simple moving average is $72.77.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.12. The firm had revenue of $353.17 million during the quarter, compared to the consensus estimate of $293.47 million. During the same quarter in the prior year, the firm posted ($0.95) earnings per share. The business’s revenue for the quarter was up 192.6% compared to the same quarter last year. Equities analysts predict that BridgeBio Pharma, Inc. will post -2.55 earnings per share for the current fiscal year.

BridgeBio Pharma Profile

(Free Report)

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.

See Also

Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report).

Institutional Ownership by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.